pharma · Acute Ischemic Stroke · Chronic Kidney Disease · DMAC
DiaMedica Therapeutics
DiaMedica Therapeutics patent portfolio — 9 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Company details
- Status
- Public
- HQ
- Minneapolis, USA
- Employees
- 45
- Programs
- 8
- Drugs
- 7
- Patents
- 9
DiaMedica Therapeutics patents
9 pharmaceutical patents indexed for DiaMedica Therapeutics. 0 expire within 24 months.
DiaMedica Therapeutics has 9 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.
Patent portfolio
-
US 12329805
Dosage forms of tissue kallikrein 1
granted -
US 11857608
Dosage forms of tissue kallikrein 1
granted -
US 11725043
Ulinastatin polypeptides
granted -
US 9839678
Human tissue kallikrein 1 glycosylation isoforms
granted -
US 9616015
Formulations of human tissue kallikrein-1 for parenteral delivery and related methods
granted -
US 9364521
Human tissue kallikrein 1 glycosylation isoforms
granted -
US 8673964
Use of drug combinations for treating insulin resistance
granted -
US 8501695
Tissue kallikrein for the treatment of diseases associated with amyloid protein
granted -
US 7622447
Use of glutathione synthesis stimulating compounds in reducing insulin resistance
granted
Frequently asked questions
How many patents does DiaMedica Therapeutics have?
9 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do DiaMedica Therapeutics patents expire?
0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.